TABLE 1.
Clinical, Demographic, Histologic, and Imaging Characteristics at Baseline and Follow-Up
| Baseline (n = 102) | Follow-Up (n = 102) | |
|---|---|---|
| Demographic | ||
| Age in years, mean (SD) | 51.7 (13.6) | 53.4 (13.5) |
| Male, n (%) | 38 (37.3) | |
| BMI (kg/m2), mean (SD) | 32.6 (5.3) | 32.7 (5.6) |
| Race/ethnicity, n (%) | ||
| White | 43 (42.2) | |
| African American | 2 (2.0) | |
| Asian | 13 (12.7) | |
| Hispanic | 40 (39.2) | |
| Other | 4 (3.9) | |
| Diabetes, n (%) | 47 (46.1) | |
| Biochemical profile | ||
| AST (U/L), median (IQR) | 35.0 (33.0) | 33.5 (30.0) |
| ALT (U/L), median (IQR) | 45.5 (46.0) | 45.5 (46.0) |
| Alkaline phosphatase (U/l), median (IQR) | 73.5 (27.0) | 75.5 (32.0) |
| Total bilirubin (mg/dL), median (IQR) | 0.4 (0.3) | 0.4 (0.3) |
| Albumin (g/dL), median (IQR) | 4.4 (0.4) | 4.5 (0.4) |
| HOMA-IR median (IQR) | 6.5 (7.4) | 7.3 (6.1) |
| Triglycerides (mg/dL), median (IQR) | 145.5 (88.0) | 144.0 (83.0) |
| Total cholesterol (mg/dL), median (IQR) | 182.0 (48.0) | 174.0 (60.0) |
| HDL (mg/dL), median (IQR) | 43.0 (18.0) | 47.0 (19.0) |
| LDL (mg/dL), median (IQR) | 99.5 (43.0) | 93.0 (46.0) |
| Platelet count (109/L), median (IQR) | 246.0 (84.0) | 235.0 (96.0) |
| Clinical prediction rule | ||
| FIB-4 | 1.3 (1.1) | 1.2 (1.1) |
| NFS | –1.3 (2.2) | –1.4 (2.1) |
| Histology | ||
| Fibrosis stage, n (%) | ||
| 0 | 27 (26.5) | 30 (29.4) |
| 1 | 36 (35.3) | 30 (29.4) |
| 2 | 12 (11.8) | 12 (11.8) |
| 3 | 17 (16.7) | 19 (18.6) |
| 4 | 10 (9.8) | 11 (10.8) |
| NASH classification, n (%) | ||
| Not NAFLD | 0 | 3 (2.9) |
| NAFLD not NASH | 8 (7.8) | 28 (27.5) |
| Borderline NASH | 2 (2.0) | 6 (5.9) |
| Definite NASH | 92 (90.2) | 65 (63.7) |
| Steatosis grade, n (%) | ||
| 0 | 1 (1.0) | 3 (2.9) |
| 1 | 35 (34.3) | 54 (52.9) |
| 2 | 41 (40.2) | 34 (33.3) |
| 3 | 25 (24.5) | 11 (10.8) |
| Lobular inflammation grade, n (%) | ||
| 0 | 0 | 1 (1) |
| 1 | 39 (38.2) | 46 (45.1) |
| 2 | 58 (56.9) | 48 (47.1) |
| 3 | 5 (4.9) | 7 (6.9) |
| Ballooning grade, n (%) | ||
| 0 | 10 (9.8) | 31 (30.4) |
| 1 | 56 (54.9) | 54 (52.9) |
| 2 | 36 (35.3) | 17 (16.7) |
| NAS median (IQR), n (%) | 5.0 (2.0) | 4.0 (2.0) |
| Imaging | ||
| Baseline MRI-PDFF (%), mean (SD) | 14.1 (10.5) | 12.5 (10.9) |
| MRE (kPa) | 2.9 (1.4) | 2.8 (1.4) |
Abbreviations: HDL, high-density lipoprotein; HOMA-IR, Homeostatic model assessment method for insulin resistance, calculated as (fasting insulin [microunits per milliliter] × fasting glucose [millimoles per liter])/22.5; LDL, low-density lipoprotein; MRI-PDFF, MRI-based proton density fat fraction; NAS, NAFLD activity score.